Orthopeutics to Present at Windhover Information and Medtech Insight's ``IN SPINE'' Conference.DALLAS -- Orthopeutics Will Be Presenting at 10:50 a.m. at Windhover wind·hov·er n. Chiefly British A kestrel. Information and Medtech Insight's Inaugural "IN SPINE" Event, Taking Place Nov. 11, 2004 at the Westin Stonebriar Resort in North Dallas North Dallas is an expansive area of numerous communities and neighborhoods in Dallas, Texas, (USA). It spans portions of three counties: Collin, Dallas, and Denton, and has strong social ties to two enclaves of Dallas (University Park and Highland Park) and a near-enclave , Texas Orthopeutics was founded to develop and commercialize revolutionary nonsurgical solutions for common orthopaedic problems. In 2003, MIT's Technology Review named injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. tissue engineering one of ten emerging technologies that will change the world, citing its aim to make conventional surgery obsolete. Orthopeutics' current focus involves a path-breaking, nonsurgical treatment to repair the intervertebral intervertebral /in·ter·ver·te·bral/ (-ver´te-bral) situated between two contiguous vertebrae; see under disk. in·ter·ver·te·bral adj. Located between vertebrae. disc, dramatically reducing disc degradation and spinal joint instability. Testing to date has demonstrated that Orthopeutics' platform technology will effectively address four current market needs: 1) a nonsurgical treatment for the prevention of degenerative disc disease Degeneration of the intervertebral disc, which is often called "degenerative disc disease" (DDD) of the spine, is a common disorder of the lower spine and for some people can cause low back pain and/or leg pain (sciatica). and the associated problem of back pain, 2) an adjunct to existing and emerging spinal surgeries to prevent adjacent level degeneration, 3) a patient-friendly solution for scoliosis Scoliosis Definition Scoliosis is a side-to-side curvature of the spine. Description When viewed from the rear, the spine usually appears perfectly straight. , and 4) improved nutritional pathways for cell-based disc therapies. Currently, a small percentage of back pain sufferers elect to have surgery. The company expects that an effective nonsurgical solution will attract a much broader market segment. Consequently these products present a market opportunity approaching $10 billion per year worldwide. Orthopeutics' testing has demonstrated the efficacy of using injectable, collagen crosslinking reagents to stabilize intervertebral joint motion by a factor of four without adversely affecting the joint's total range of motion. Nonsurgical EXogenous Exogenous Describes facts outside the control of the firm. Converse of endogenous. crosslink Therapy (NEXT) can be completely non-toxic and effective almost immediately after injection. Other experiments have demonstrated an improvement in the disc's durability, and an increase in "bounce back" from deformity-increasing bends. Furthermore, NEXT doubles fluid flow to the central disc, providing an increased supply of nutrients to bolster the disc's ability to self-repair the tissue. NEXT acts in harmony with the body's own efforts to stabilize aging and mechanically unstable discs. Collagen crosslinks are known to serve as "sacrificial bonds," dissipating disruptive energy and protecting the tissue from degradation. Their role is particularly important in biologically-limited, avascular avascular /avas·cu·lar/ (a-vas´ku-ler) not vascular; bloodless. a·vas·cu·lar adj. Not associated with or supplied by blood vessels. , load-bearing tissues like the spinal disc. Orthopeutics has pending domestic and international patents covering the use of directly applied non-toxic and minimally toxic crosslinking reagents for these purposes along with the associated devices, reagents and methods. As part of his twenty years TWENTY YEARS. The lapse of twenty years raises a presumption of certain facts, and after such a time, the party against whom the presumption has been raised, will be required to prove a negative to establish his rights. 2. in spine research, Orthopeutics' founder, Tom Hedman, was the inventor of an artificial disc in the '80s. The company has raised $500k from an STTR STTR Small Business Technology Transfer Program STTR Stator STTR Small Technology Transfer Innovation Research grant and angel investors to date. The company is looking to form a licensing arrangement with contract funding as part of a strategic alliance with a spinal device company. The company's website can be found at: www.orthopeutics.com. About Medtech Insight Medtech Insight's medical technology investment conferences are considered the premier forum for senior executives in the investment and medical technology community to preview emerging medtech companies in need of funding, acquisition and/or strategic partnership. Medtech Insight, which was recently acquired by Windhover Information Inc. (www.windhover.com), publisher of "IN VIVO in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. : The Business & Medicine Report," and "Start-UP: Windhover's Review of Emerging Technologies," offers a wide variety of products and services for the medical technology executive. In addition to conferences, the company publishes the "medtech insight" newsletter, a monthly publication covering the latest trends and innovations in the medical technology industry, as well as analyses of medtech markets through its Reports group, and offers custom consulting and market research. To register for the IN SPINE conference or for more information on Medtech Insight, please call Scott Pantel at 949-219-0150 or 888-290-2225 toll-free in the U.S., e-mail sales@medtechinsight.com, or visit http://www.medtechinsight.com/inspine-01.html. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion